Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPN | P05981 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20543732 | 1.00 | POLB (0.35) | POLBMEN1KMT2AHPNUSP2 | |
| SCHEMBL20543592 | 0.95 | NPY5R (0.35) | POLBMEN1KMT2AHPNUSP2 | |
| SCHEMBL30110500 | 0.95 | NPY5R (0.35) | POLBMEN1KMT2AHPNUSP2 | |
| SCHEMBL25760310 | 0.91 | RAB9A (0.36) | MEN1KMT2AALDH1A1NPY5RNPC1 | |
| SCHEMBL19206668 | 0.91 | NPY5R (0.38) | POLBMEN1KMT2AMAPK1HSD17B10 | |
| SCHEMBL21751384 | 0.90 | CASR (0.37) | MEN1KMT2AALDH1A1NPY5RALKBH3 | |
| SCHEMBL21879010 | 0.86 | GNRHR (0.34) | MEN1KMT2AADORA3ADORA2AADORA2B | |
| SCHEMBL30110484 | 0.86 | GNRHR (0.34) | MEN1KMT2AADORA3ADORA2AADORA2B | |
| SCHEMBL20543878 | 0.86 | HPN (0.35) | POLBMEN1KMT2AHPNUSP2 | |
| SCHEMBL27213496 | 0.86 | ALDH1A1 (0.41) | POLBHPNUSP2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964501-B1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | PASTEUR INSTITUT (FR) | 2024-09-04 | — | — | EP | claimed |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| EP-4392460-A1 | LUMINESCENT BASED ANTIGEN ASSAY | Institut Pasteur (FR) | 2024-07-03 | — | — | EP | disclosed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | disclosed |
| CN-118139895-A | Luminescence-based antigen assay | 巴斯德研究所 | 2024-06-04 | — | — | CN | disclosed |
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2024-03-26 | — | — | US | disclosed |
| EP-4143306-A1 | LUCIFERASE LINKED IMMUNOSORBENT ASSAY | Institut Pasteur (FR) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023025816-A1 | LUMINESCENT BASED ANTIGEN ASSAY | INSTITUT PASTEUR (FR) | 2023-03-02 | — | — | WO | disclosed |
| CN-115461454-A | Luciferase coupled immunosorbent assay | 巴斯德研究所 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938199-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | NISCH, HLCS, CYP3A5 | POLB 2872/4885MEN1 1101/4885KMT2A 2961/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | POLB 4397/4885MEN1 2850/4885KMT2A 4770/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | POLB 4259/4885MEN1 2885/4885KMT2A 4589/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | POLB 2872/4885MEN1 1101/4885KMT2A 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.